AMPH (Amphastar Pharmaceuticals) Marketable Securities: $121.0 Mil (As of Mar. 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $19.61
GF Value $48.83
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Marketable Securities?

Amphastar Pharmaceuticals AMPH -0.15% 83 Marketable Securities is $121.0 Mil as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.83 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Amphastar Pharmaceuticals's Marketable Securities for the quarter that ended in Mar. 2026 was $121.0 Mil.

Amphastar Pharmaceuticals's annual Marketable Securities declined from Dec. 2023 ($112.5 Mil) to Dec. 2024 ($70.0 Mil) but then increased from Dec. 2024 ($70.0 Mil) to Dec. 2025 ($112.6 Mil).

Amphastar Pharmaceuticals  (NAS:AMPH) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Amphastar Pharmaceuticals Marketable Securities Related Terms

Amphastar Pharmaceuticals Marketable Securities Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Marketable Securities Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.32 19.66 112.51 70.04 112.64

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.10 44.06 59.94 112.64 121.01
AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $121.0 Mil mean?
Amphastar Pharmaceuticals (AMPH) has a Marketable Securities of $121.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Marketable Securities too high?
Amphastar Pharmaceuticals' current Marketable Securities is $121.0 Mil. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Marketable Securities compare to ETON and PCRX?
Amphastar Pharmaceuticals' Marketable Securities of $121.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Drug Manufacturers company?
A good Marketable Securities depends on the Drug Manufacturers industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Marketable Securities is $121.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.83, compared to a current price of $19.61 — trading 59.8% below its estimated fair value. The current Marketable Securities is $121.0 Mil. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Marketable Securities is $121.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $19.61 is trading 59.8% below its estimated GF Value™ of $48.83. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Marketable Securities: $121.0 Mil
  • GF Value™: $48.83 vs. price of $19.61 (59.8% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.61
Price
$48.83
GF Value